Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Myostatin blockade with a fully human monoclonal antibody induces muscle hypertrophy and reverses muscle atrophy in young and aged mice

Open access

Abstract

BACKGROUND: Loss of skeletal muscle mass and function in humans is associated with significant morbidity and mortality. The role of myostatin as a key negative regulator of skeletal muscle mass and function has supported the concept that inactivation of myostatin could be a useful approach for treating muscle wasting diseases. METHODS: We generated a myostatin monoclonal blocking antibody (REGN1033) and characterized its effects in vitro using surface plasmon resonance biacore and cell-based Smad2/3 signaling assays. REGN1033 was tested in mice for the ability to induce skeletal muscle hypertrophy and prevent atrophy induced by immobilization, hindlimb suspension, or dexamethasone. The effect of REGN1033 on exercise training was tested in aged mice. Messenger RNA sequencing, immunohistochemistry, and ex vivo force measurements were performed on skeletal muscle samples from REGN1033-treated mice. RESULTS: The human monoclonal antibody REGN1033 is a specific and potent myostatin antagonist. Chronic treatment of mice with REGN1033 increased muscle fiber size, muscle mass, and force production. REGN1033 prevented the loss of muscle mass induced by immobilization, glucocorticoid treatment, or hindlimb unweighting and increased the gain of muscle mass during recovery from pre-existing atrophy. In aged mice, REGN1033 increased muscle mass and strength and improved physical performance during treadmill exercise. CONCLUSIONS: We show that specific myostatin antagonism with the human antibody REGN1033 enhanced muscle mass and function in young and aged mice and had beneficial effects in models of skeletal muscle atrophy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13395-015-0060-8

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Effects of myostatin, GDF11, and activin A on Smad2/3 activity. a Smad2/3 activity was recorded as relative luminescence units (RLU) from A204/Smad2/3/Luc reporter cells in the presence of increasing concentrations of myostatin, GDF11, or activin A. Smad2/3 activity in the presence of constant myostatin (b), GDF11 (c), or activin A (d) concentrations and increasing concentrations of control antibody (circles), REGN1033 (squares), and ActR2B-hFc (triangles). e Phospho-Smad2 (p-Smad2) and total Smad2/3 western blot from human skeletal myoblasts in the absence and presence of myostatin, GDF11, or activin A and either control antibody (Control mAb), ActRIIB-hFc, or REGN1033
Fig. 1 Effects of myostatin, GDF11, and activin A on Smad2/3 activity. a Smad2/3 activity was recorded as relative luminescence units (RLU) from A204/Smad2/3/Luc reporter cells in the presence of increasing concentrations of myostatin, GDF11, or activin A. Smad2/3 activity in the presence of constant myostatin (b), GDF11 (c), or activin A (d) concentrations and increasing concentrations of control antibody (circles), REGN1033 (squares), and ActR2B-hFc (triangles). e Phospho-Smad2 (p-Smad2) and total Smad2/3 western blot from human skeletal myoblasts in the absence and presence of myostatin, GDF11, or activin A and either control antibody (Control mAb), ActRIIB-hFc, or REGN1033CC BY · PubMed Central
Fig. 2 Effects of REGN1033 on muscle mass, muscle fiber area, and number and force. a Gastrocnemius anterior (GA) muscle weight after 4 weeks of treatment with REGN1033 at 0.1, 0.75, 2.5, 10, or 30 mg/kg in CB17-SCID mice. Irrelevant isotype antibody was used as control. Muscle weights were normalized by starting body weights and expressed as percent changes from isotype control. b GA and tibialis anterior (TA) muscle weights normalized by starting body weight and expressed as percent changes from isotype control in CB17-SCID and C57BL/6 mice dosed at 10 mg/kg for 3–4 weeks. c Heart weights normalized by starting body weight and expressed as percent changes from isotype control in CB17-SCID mice dosed at 10 mg/kg for 4 weeks. d H&E staining of TA muscle from isotype control antibody and REGN1033-treated CB17-SCID mice for 4 weeks. Muscle fiber size distribution (e), fiber count (f), and fiber type (g) of GA muscle from CB17-SCID mice after 4-week treatment with 10 mg/kg of control antibody or REGN1033. Muscle fiber type and number are representatives of five independent studies. h Isometric force as a function of stimulation frequency of TA muscle at the end of 3 weeks of treatment with isotype control antibody or REGN1033. Peak tetanic force (i) and specific force (j) from the experiment shown in h. All groups had 5–10 animals. Data are means ± SEM. *P < 0.05, ***P < 0.001, ****P < 0.0001 isotype vs. control
Fig. 2 Effects of REGN1033 on muscle mass, muscle fiber area, and number and force. a Gastrocnemius anterior (GA) muscle weight after 4 weeks of treatment with REGN1033 at 0.1, 0.75, 2.5, 10, or 30 mg/kg in CB17-SCID mice. Irrelevant isotype antibody was used as control. Muscle weights were normalized by starting body weights and expressed as percent changes from isotype control. b GA and tibialis anterior (TA) muscle weights normalized by starting body weight and expressed as percent changes from isotype control in CB17-SCID and C57BL/6 mice dosed at 10 mg/kg for 3–4 weeks. c Heart weights normalized by starting body weight and expressed as percent changes from isotype control in CB17-SCID mice dosed at 10 mg/kg for 4 weeks. d H&E staining of TA muscle from isotype control antibody and REGN1033-treated CB17-SCID mice for 4 weeks. Muscle fiber size distribution (e), fiber count (f), and fiber type (g) of GA muscle from CB17-SCID mice after 4-week treatment with 10 mg/kg of control antibody or REGN1033. Muscle fiber type and number are representatives of five independent studies. h Isometric force as a function of stimulation frequency of TA muscle at the end of 3 weeks of treatment with isotype control antibody or REGN1033. Peak tetanic force (i) and specific force (j) from the experiment shown in h. All groups had 5–10 animals. Data are means ± SEM. *P < 0.05, ***P < 0.001, ****P < 0.0001 isotype vs. controlCC BY · PubMed Central
Fig. 3 Myostatin, latent complex, and precursor forms bound by REGN1033 in vivo. a Antibody complexes present in serum samples from C17-SCID mice that had received multiple REGN1033 or isotype-matched control antibody injections over 28 days were collected by immunoprecipitation, separated by non-reducing SDS-PAGE, and immunoblotted with a myostatin antibody. The first lane contains conditioned medium from CHO cells transiently transfected with myostatin precursor expression vector to serve as a positive control; two independent serum immunoprecipitations from control or REGN1033-treated mice are shown. Arrows indicate mature myostatin homodimer, unprocessed precursor, and myostatin monomer (M). Asterisk indicates myostatin form believed to be partially processed precursor. All samples were resolved on the same gel and appropriate lanes are juxtaposed for clarity. b Duplicate samples as described in a were probed with a myostatin propeptide antibody. Arrow indicates cleaved prodomain which co-precipitates in complex with mature myostatin, arrowhead indicates unprocessed precursor, and asterisks indicate partially processed precursor forms. c Sera from WT and Mstn −/− mice was probed with the myostatin antibody to demonstrate specificity. Arrows indicate myostatin precursor and mature myostatin homodimer, and the asterisk indicates partially processed precursor, all of which are absent in the Mstn −/− sample
Fig. 3 Myostatin, latent complex, and precursor forms bound by REGN1033 in vivo. a Antibody complexes present in serum samples from C17-SCID mice that had received multiple REGN1033 or isotype-matched control antibody injections over 28 days were collected by immunoprecipitation, separated by non-reducing SDS-PAGE, and immunoblotted with a myostatin antibody. The first lane contains conditioned medium from CHO cells transiently transfected with myostatin precursor expression vector to serve as a positive control; two independent serum immunoprecipitations from control or REGN1033-treated mice are shown. Arrows indicate mature myostatin homodimer, unprocessed precursor, and myostatin monomer (M). Asterisk indicates myostatin form believed to be partially processed precursor. All samples were resolved on the same gel and appropriate lanes are juxtaposed for clarity. b Duplicate samples as described in a were probed with a myostatin propeptide antibody. Arrow indicates cleaved prodomain which co-precipitates in complex with mature myostatin, arrowhead indicates unprocessed precursor, and asterisks indicate partially processed precursor forms. c Sera from WT and Mstn −/− mice was probed with the myostatin antibody to demonstrate specificity. Arrows indicate myostatin precursor and mature myostatin homodimer, and the asterisk indicates partially processed precursor, all of which are absent in the Mstn −/− sampleCC BY · PubMed Central
Fig. 4 Gene expression in GA muscle from REGN1033 treated mice. Gene changes (twofold, p < 0.01) in GA muscle from CB17-SCID (a) and C57BL/6 (b) mice dosed at 10 mg/kg for 3 to 4 weeks. Results are expressed in reads per kilobase per million (RKPM). Data are means ± SEM of four mice
Fig. 4 Gene expression in GA muscle from REGN1033 treated mice. Gene changes (twofold, p < 0.01) in GA muscle from CB17-SCID (a) and C57BL/6 (b) mice dosed at 10 mg/kg for 3 to 4 weeks. Results are expressed in reads per kilobase per million (RKPM). Data are means ± SEM of four miceCC BY · PubMed Central
Fig. 5 REGN1033 prevents muscle atrophy by immobilization and dexamethasone treatment. a GA muscle weights from mice in which the right hindlimbs were immobilized for 14 days. REGN1033 or isotype control antibody was dosed during the 14-day immobilization period. Results are expressed as the percent change compared to muscle weights of non-immobilized limbs. Statistical significance vs. non-immobilized control is indicated. b TA and GA muscle weights from C57BL/6 mice implanted with osmotic pumps delivering saline or dexamethasone (Dex; 23 μg/day) and simultaneously treated with REGN1033 or isotype control antibody (10 mg/kg) for 2 weeks. Results are presented as the percent change compared to muscle weights of the saline pump control group. Statistical significance vs. saline control is indicated as asterisk, whereas significance vs. Dex plus isotype control is indicated as number sign. c Isometric force as a function of stimulation frequency of TA muscle from mice implanted with osmotic pumps delivering saline or dexamethasone (Dex) and treated with REGN1033 or isotype control antibody (10 mg/kg) for 2 weeks. Statistical significance vs. saline control is indicated as asterisk, whereas significance vs. Dex plus isotype control is indicated as number sign. Similar to c but depicting peak tetanic force (d) or specific force (e). All groups had 5–12 animals. Data are means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 and ## P < 0.01, ### P < 0.001, #### P < 0.0001
Fig. 5 REGN1033 prevents muscle atrophy by immobilization and dexamethasone treatment. a GA muscle weights from mice in which the right hindlimbs were immobilized for 14 days. REGN1033 or isotype control antibody was dosed during the 14-day immobilization period. Results are expressed as the percent change compared to muscle weights of non-immobilized limbs. Statistical significance vs. non-immobilized control is indicated. b TA and GA muscle weights from C57BL/6 mice implanted with osmotic pumps delivering saline or dexamethasone (Dex; 23 μg/day) and simultaneously treated with REGN1033 or isotype control antibody (10 mg/kg) for 2 weeks. Results are presented as the percent change compared to muscle weights of the saline pump control group. Statistical significance vs. saline control is indicated as asterisk, whereas significance vs. Dex plus isotype control is indicated as number sign. c Isometric force as a function of stimulation frequency of TA muscle from mice implanted with osmotic pumps delivering saline or dexamethasone (Dex) and treated with REGN1033 or isotype control antibody (10 mg/kg) for 2 weeks. Statistical significance vs. saline control is indicated as asterisk, whereas significance vs. Dex plus isotype control is indicated as number sign. Similar to c but depicting peak tetanic force (d) or specific force (e). All groups had 5–12 animals. Data are means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 and ## P < 0.01, ### P < 0.001, #### P < 0.0001CC BY · PubMed Central
Fig. 6 Effects of REGN1033 on muscle atrophy induced by hindlimb unloading. a TA and GA muscle mass after treatment with REGN1033 or an isotype control antibody during 7 days of hindlimb unloading (HLS). One group of mice served as control to the HLS group and received injections with the isotype control antibody. Weights were normalized according to starting body weight, and data are expressed as percent change from normalized non-hindlimb suspended control group. Significance was calculated over normalized non-hindlimb suspended isotype control group (asterisk) or over normalized hindlimb suspended isotype control group (number sign). b Muscle weights at the end of 7 days of hindlimb unloading (HLS) or 7 days of HLS plus 7 days of recovery (HLS + rec). Groups of mice were dosed with isotype control or REGN1033 (10 mg/kg) during the 7-day recovery period. Changes in muscle weights are depicted as the difference in muscle weights compared to the no-hindlimb-suspended group. Statistical significance was calculated vs. animals that were not-hindlimb-suspended (no HLS) or against animals that were hindlimb-suspended for 7 days (7-day HLS). All groups had four to six animals. Data are means ± SEM. *P < 0.05, **P < 0.01, ****P < 0.0001 and ## P < 0.01, ### P < 0.001, #### P < 0.0001
Fig. 6 Effects of REGN1033 on muscle atrophy induced by hindlimb unloading. a TA and GA muscle mass after treatment with REGN1033 or an isotype control antibody during 7 days of hindlimb unloading (HLS). One group of mice served as control to the HLS group and received injections with the isotype control antibody. Weights were normalized according to starting body weight, and data are expressed as percent change from normalized non-hindlimb suspended control group. Significance was calculated over normalized non-hindlimb suspended isotype control group (asterisk) or over normalized hindlimb suspended isotype control group (number sign). b Muscle weights at the end of 7 days of hindlimb unloading (HLS) or 7 days of HLS plus 7 days of recovery (HLS + rec). Groups of mice were dosed with isotype control or REGN1033 (10 mg/kg) during the 7-day recovery period. Changes in muscle weights are depicted as the difference in muscle weights compared to the no-hindlimb-suspended group. Statistical significance was calculated vs. animals that were not-hindlimb-suspended (no HLS) or against animals that were hindlimb-suspended for 7 days (7-day HLS). All groups had four to six animals. Data are means ± SEM. *P < 0.05, **P < 0.01, ****P < 0.0001 and ## P < 0.01, ### P < 0.001, #### P < 0.0001CC BY · PubMed Central
Fig. 7 Effects of REGN1033 on muscle mass and exercise performance in aged mice. a TA and GA muscle weights of 24-month-old mice receiving REGN1033 or isotype control antibody treatment (10 mg/kg) for 3 weeks. Muscle weights were normalized by starting body weights and expressed as percent changes from isotype control. b Isometric force as a function of stimulation frequency of TA muscle at the end of 3 weeks of treatment with isotype control antibody or REGN1033. Same as in b but depicting peak tetanic TA muscle force (c) or specific force (d). TA (e) and GA (f) muscle weights at the end of 3 weeks of treatment with REGN1033 or isotype control antibody (10 mg/kg) from 19-month-old C57BL/ mice either left sedentary or during a three week exercise regimen. Muscle weights were normalized by starting body weights and expressed as percent changes from isotype control. g, h Treadmill exhaustion and maximal running capacity tests measured in the mice described in e, f. All groups had six to eight animals. Data are means ± SEM. *P < 0.05, **P < 0.01, ****P < 0.0001 vs. sedentary isotype control and ## P < 0.01 vs. sedentary REGN1033
Fig. 7 Effects of REGN1033 on muscle mass and exercise performance in aged mice. a TA and GA muscle weights of 24-month-old mice receiving REGN1033 or isotype control antibody treatment (10 mg/kg) for 3 weeks. Muscle weights were normalized by starting body weights and expressed as percent changes from isotype control. b Isometric force as a function of stimulation frequency of TA muscle at the end of 3 weeks of treatment with isotype control antibody or REGN1033. Same as in b but depicting peak tetanic TA muscle force (c) or specific force (d). TA (e) and GA (f) muscle weights at the end of 3 weeks of treatment with REGN1033 or isotype control antibody (10 mg/kg) from 19-month-old C57BL/ mice either left sedentary or during a three week exercise regimen. Muscle weights were normalized by starting body weights and expressed as percent changes from isotype control. g, h Treadmill exhaustion and maximal running capacity tests measured in the mice described in e, f. All groups had six to eight animals. Data are means ± SEM. *P < 0.05, **P < 0.01, ****P < 0.0001 vs. sedentary isotype control and ## P < 0.01 vs. sedentary REGN1033CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Research works printed but not linked: 2

  1. LeBrasseur NK, Schelhorn TM, Bernardo BL, Cosgrove PG, Loria PM, Brown TA. Myostatin inhibition enhances the effects of exercise on performance and metabolic outcomes in aged mice. J Gerontol A Biol Sci Med Sci. 2009;64A(9):940–8. · DOI · Paper page
  2. Bernardo BL, Wachtmann TS, Cosgrove PG, Kuhn M, Opsahl AC, Judkins KM, et al. Postnatal PPARdelta activation and myostatin inhibition exert distinct yet complimentary effects on the metabolic profile of obese insulin-resistant mice. PLoS One. 2010;5(6):e11307. · DOI

Cited by

See all 159

Metadata

Authors
Latres, E., Pangilinan, J., Miloscio, L., Bauerlein, R., Na, E., Potocky, T. B., Huang, Y., Eckersdorff, M., Rafique, A., Mastaitis, J., Lin, C., Murphy, A. J., Yancopoulos, G. D., Gromada, J., & Stitt, T.
Affiliations
Regeneron (United States) (US)
Corresponding author
Gromada, Jesper
Venue
Skeletal Muscle
Published
2015-10-09
Volume
5
Issue
1
Pages
34-34
ISSN
2044-5040 (ISSN-L)
OpenAlex
W2114952053
Cited by
143
References
36
Citations by year
2026: 10 · 2025: 13 · 2024: 10 · 2023: 15 · 2022: 6 · 2021: 18 · 2020: 13 · 2019: 21 · 2018: 14 · 2017: 13 · 2016: 10
FWCI
5.36
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Skeletal Muscle (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
  • Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
Keywords
myostatin, monoclonal antibodies, skeletal muscle hypertrophy, muscle atrophy, Smad2/3 signaling, immobilization, dexamethasone, hindlimb unloading, aging, exercise training, muscle strength, muscle mass

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Myostatin blockade with a fully human monoclonal antibody induces muscle hypertrophy and reverses muscle atrophy in young and aged mice. https://app.cochat.ai/papers/10.1186/s13395-015-0060-8
The paper
Latres, E., Pangilinan, J., Miloscio, L., Bauerlein, R., Na, E., Potocky, T. B., Huang, Y., Eckersdorff, M., Rafique, A., Mastaitis, J., Lin, C., Murphy, A. J., Yancopoulos, G. D., Gromada, J., & Stitt, T. (2015). Myostatin blockade with a fully human monoclonal antibody induces muscle hypertrophy and reverses muscle atrophy in young and aged mice. Skeletal Muscle. https://doi.org/10.1186/s13395-015-0060-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.